Psychopharmacology Maastricht
The psychopharmacology department at Maastricht University focuses on the cognitive, behavioral, and biological effects of various substances, ranging from pharmaceutical to recreational drugs.
Learn More
Maastricht Psychedelic Symposium
On May 24, the Maastricht Psychedelic Research Team organized a mini-symposium on psychedelics. We welcomed two international speakers: Prof. dos Santos and Prof. Bouso from Brazil and Spain to discuss their ayahuasca and ibogaine research. We also had several internal speakers: presenting on mystical vs. autobiographical psychedelic experiences (Dr Kangaslampi), microdosing (Ms. Haijen), and 5-MeO-DMT (Mr. Reckweg).
Click below to watch the entire symposium
Read about our new paper on the neurological origins of a visual psychedelic hallucination
Congratulations to Zeus Tipado on his newly published paper that introduces a new theory as to why a person experiences a visual trip on psychedelics.
Read The PaperParticipate in our studies!
We're always conducting research in our department and we're frequently looking for participants to be a part of science! If you're interested, look at the studies that we are currently conducting.
View All Studies
Our Scientists
Mauro Cavarra, MSc
Psychosomatics, Chronic Pain, Psychedelic-Assisted Psychotherapy
I am a psychotherapist, hypnotherapist and clinical trainer interested in understanding the connection between mind and body. At the Department I work in research projects that explore the potential of psychedelic therapies in the treatment...
Eline Haijen, MSc
ADHD, Microdosing, Psychedelics
I am a PhD candidate in the Psychopharmacology in Maastricht research group at the Department of Neuropsychology and Psychopharmacology at Maastricht University. I am from a little village close to Maastricht.
Johannes Reckweg, MSc
5-MeO-DMT, Neuropsychopharmacology, Therapy
I am Johannes, a PhD candidate from Germany. After receiving my Bachelor’s degree from the Rijksuniversiteit Groningen, I came to Maastricht for my Master in Neuropsychology.
Dr. Rudy Schreiber
CNS Drug Discovery, Research Domain Criteria
I started my career in central nervous system drug discovery in 1993 and subsequently progressed from bench scientist to senior leadership roles at global pharmaceutical companies
Aedan O’Shea, MSc
I have a long standing interest in unravelling the therapeutic mechanisms of Psychedelics, and in this project I will investigate the effect of Psychedelic drug exposure in humans on miRNA’s transported in neuron-derived Extracellular Vesicles...
Zeus Tipado, MSc
My neuroscience research is focused on perceptual experiences of psychedelics, specifically visual experiences while under DMT.
Dr. Conny Quaedflieg
Intentional Forgetting, EEG, Stress Resilience
Through my extensive research experience, I have built expertise in various disciplines (psychology, psychophysiology, neurosciences) and I have become enthusiastic about bridging them.
Dr. Samuli Kangaslampi
Most of my previous research has focused on psychological trauma, trauma-related disorders, trauma-focused psychotherapies, as well as autobiographical memory.
Dr. Malin Vedøy Uthaug
Ayahuasca, 5-MeO-DMT, Consciousness
I am an altered states of consciousness researcher from Norway and one of the world leading experts on 5-MeO-DMT.
Psychedelic Research
Microdosing psychedelics: More questions than answers? An overview and suggestions for future research
→
Mood and cognition after administration of low LSD doses in healthy volunteers: A placebo controlled dose-effect finding study
→
Ayahuasca enhances creative divergent thinking while decreasing conventional convergent thinking
creativity, divergent thinking, convergent thinking, Ayahuasca
→
Ritualistic use of ayahuasca enhances a shared functional connectome identity with others
Functional Connectivity, Ayahuasca, Ritual
→
Cannabis Research
Comparison of Cannabinoid Pharmacokinetic Properties in Occasional and Heavy Users Smoking a Marijuana or Placebo Joint
→
Intoxication by a synthetic cannabinoid (JWH-018) causes cognitive and psychomotor impairment in recreational cannabis users
Cognition, Psychomotor, Cannabis
→
Medicinal Δ9-tetrahydrocannabinol (dronabinol) impairs on-the-road driving performance of occasional and heavy cannabis users but is not detected in Standard Field Sobriety Tests
→
Get in Touch
We are always up for communicating with people that have interesting ideas or questions. If you want to contact our department, please reach out using this form below.